Bayesian designs to account for patient heterogeneity in phase II clinical trials

Peter F. Thall; J. Kyle Wathen

doi:10.1097/CCO.0b013e328302163c

Bayesian designs to account for patient heterogeneity in phase II clinical trials

Peter F. Thall, J. Kyle Wathen

Biostatistics

Research output: Contribution to journal › Review article › peer-review

10 Scopus citations

Abstract

Due to the rapidly increasing number of potential new treatments to be evaluated clinically, increasing costs and limited resources, it is critically important to perform early phase clinical trials efficiently. The new Bayesian methods described here and other related methods provide efficient, broadly applicable tools to address these problems.

Original language	English (US)
Pages (from-to)	407-411
Number of pages	5
Journal	Current opinion in oncology
Volume	20
Issue number	4
DOIs	https://doi.org/10.1097/CCO.0b013e328302163c
State	Published - Jul 2008

Keywords

Analysis of covariance
Bayesian design
Hierarchical model
Phase II clinical trial

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1097/CCO.0b013e328302163c

Cite this

@article{38813d0e7fea44a586f8f18024df7fa1,

title = "Bayesian designs to account for patient heterogeneity in phase II clinical trials",

abstract = "Due to the rapidly increasing number of potential new treatments to be evaluated clinically, increasing costs and limited resources, it is critically important to perform early phase clinical trials efficiently. The new Bayesian methods described here and other related methods provide efficient, broadly applicable tools to address these problems.",

keywords = "Analysis of covariance, Bayesian design, Hierarchical model, Phase II clinical trial",

author = "Thall, {Peter F.} and Wathen, {J. Kyle}",

year = "2008",

month = jul,

doi = "10.1097/CCO.0b013e328302163c",

language = "English (US)",

volume = "20",

pages = "407--411",

journal = "Current opinion in oncology",

issn = "1040-8746",

publisher = "Lippincott Williams and Wilkins",

number = "4",

}

TY - JOUR

T1 - Bayesian designs to account for patient heterogeneity in phase II clinical trials

AU - Thall, Peter F.

AU - Wathen, J. Kyle

PY - 2008/7

Y1 - 2008/7

N2 - Due to the rapidly increasing number of potential new treatments to be evaluated clinically, increasing costs and limited resources, it is critically important to perform early phase clinical trials efficiently. The new Bayesian methods described here and other related methods provide efficient, broadly applicable tools to address these problems.

AB - Due to the rapidly increasing number of potential new treatments to be evaluated clinically, increasing costs and limited resources, it is critically important to perform early phase clinical trials efficiently. The new Bayesian methods described here and other related methods provide efficient, broadly applicable tools to address these problems.

KW - Analysis of covariance

KW - Bayesian design

KW - Hierarchical model

KW - Phase II clinical trial

UR - http://www.scopus.com/inward/record.url?scp=47249119314&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=47249119314&partnerID=8YFLogxK

U2 - 10.1097/CCO.0b013e328302163c

DO - 10.1097/CCO.0b013e328302163c

M3 - Review article

C2 - 18525336

AN - SCOPUS:47249119314

SN - 1040-8746

VL - 20

SP - 407

EP - 411

JO - Current opinion in oncology

JF - Current opinion in oncology

IS - 4

ER -

Bayesian designs to account for patient heterogeneity in phase II clinical trials

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this